source
- Supernus and Individor to merge, creating $2 billion brain-drug companySupernus and Individor announced a merger that will combine their portfolios of neurological medicines. The two firms together generated about $2 billion in revenue in 2025 from roughly a dozen CN…
- FDA releases new guidances on adhesive performance and skin irritation studies for transdermal generic drugsThe U.S. Food and Drug Administration has issued two new guidances that address transdermal or topical delivery systems for generic drugs. One is a final guidance that outlines how to assess adhesi…